Dexcom CEO Jake Leach on Continuous Glucose Monitoring (CGM) Innovation, the CONNECT Study and What’s Next for Glucose Monitoring at ADA 2026
from GlucoseTech | Continuous Glucose Monitoring (CGM) Education for Healthcare Providers
26m 33s
DEXCOM’s continuous glucose monitoring (CGM) technology has advanced dramatically over the past two decades, evolving from a physician-only tool to a user-friendly, clinically impactful solution for patients with diabetes and even those without. In recent developments, DEXCOM launched the 15-day G7 sensor, offering longer wear time, improved algorithm accuracy, and smoother glucose trend visualization, with a new adhesive patch increasing sensor durability without causing irritation. The company is introducing key clinical tools like Smart Basal and Smart Bolus to help clinicians optimize insulin therapy, with real-world results showing patients reach optimal doses in as little as 17 days. A major highlight is the CONNECT study, a large randomized trial showing that CGM improves glycemic control—reducing A1C by nearly 1%—and lowers diabetes distress across all types of diabetes, including non-insulin users. DEXCOM’s partnership with Nutrient Sense enables personalized, CGM-driven nutrition plans, boosting patient engagement. The company emphasizes that glucose monitoring is not just for diabetes but also vital for metabolic health and longevity. To ensure continuous improvement, DEXCOM runs a Customer Advisory Council that provides unfiltered user feedback. Additionally, the company is actively advocating for broader insurance coverage, aiming to make CGM accessible to all patients with diabetes. These innovations reflect a strategic commitment to empowering both patients and clinicians with actionable, real-time glucose insights that drive better health outcomes.
Welcome to Glucose Tech. This is a podcast dedicated to US-based healthcare providers
treating patients with diabetes. "Dose smart basal is one of those technologies that's
in a pilot launch right now. We've got it in quite a few clinics across the US. Seeing
great results, I just saw a patient that within 17 days got to their optimal dose. When you think
about health and longevity, I think as we continue to study that, we're going to see that Glucose
is a very important vital sign that needs to be monitored and people need to have education about it."
"I have not met a single person who has worn a CGM and not learned something."
Welcome back to Glucose Tech, the podcast bringing healthcare professionals practical conversations
on continuous Glucose monitoring. I'm your host, SharePass Story, and we're coming to live from
ADA 2026. In today's episode, we're exploring the latest innovations from DEXCOM
and discussing how the CGM landscape continues to evolve to better support patients
and the conditions who serve them. Joining us today is Jake Leach, President and CEO of DEXCOM.
He's going to be sharing his perspective on the company's latest advancements
in the future of CGM technology and what's next for the industry. Jake, thanks for joining us today.
Hi, Share, it's great to be here. I think we've tried to get this to happen a couple of times
and now we're finally here today. "Here we are, yeah, in person, which is much better because
sometimes you have to do it virtually. So it's so great to be here with you today. So what we're
really going to focus on, and we talk about how DEXCOM or really CGM technology in general,
right? Of course, is how it's helping clinicians, how can they implement it into practice,
how can they kind of sort through all this technology, like what is really meaningful to them
and to their patients. Does that sound good? Sounds great. All right, awesome. So let's just get
into it. So let me just ask you. So from your perspective, let's kind of talk about the evolution
of CGM technology. I know you've been here for 20 years, 21. 22. 22. And then eight years before
that at another CGM company. Wow, okay. So can you just talk about, you know, how is it evolved,
and where are we now? And there's so much has changed really in the past 10 years.
So how do the clinicians kind of sift through all of that? Yeah, it's a really important question,
as you think about the evolution of CGM over the basically the last three decades. You know,
it started as a blinded product that was only the data was only visible to the physicians.
And then now it is such an empowering tool. I think some of the biggest things have changed
is the usability of the products. And every component of like the accuracy of their liability,
how the data is available, you know, integration with the smartphones. There's so many innovations
that have occurred that make the products easier to use for both the patients as well as the
clinicians. I remember in the early days, there was a lot of question around the amount of data
and how is it going to be used by the users and the clinicians as well. And I think as we've developed
more and more technology around the sensor software clarity, the patients and the physicians
can interact with it. You know, spotting patterns is one of the big things that we implemented
in the clarity that really started to interpret the data for physicians instead of them having
a comb through, you know, days and days of data. Really, the idea is it points you to the most
impactful areas for that patient and what they need to work on from a therapy perspective.
Because a big part of what we're trying to do is optimize diabetes therapy. A lot of it is
around diet activity, but there's a really significant part around medication. And so we're
starting to launch new tools to help physicians and patients better manage their medications.
Yeah, and I mean, I remember so I was in practice as a dietitian diabetes educator
and clarity was my favorite software. I loved the overview report. But because it would help,
you could just quickly look at it, right? And you know where you're going to focus that conversation.
Do I need to focus on hypoglycemia, hyper, how much time and range? And it really helps you. So,
so I love that. We talked about that because I think it's important for our listeners out there
to know that at Dexcom, we're really trying to always focus on the person, whether they have diabetes
or they don't. They just want to help their metabolic health. So whatever's happening with the person,
we're trying to make the feature for them. Can you talk to that a little bit? Yeah, sure. So we're
always trying to meet a need for users, whether it's a prescribing physician or a physician's
interpreting data or the patient who's wearing the product. And one of the unique things that's
happened over time is CGM, when we first started developing the technology, we were very focused on
replacing finger sticks for people who have type one diabetes because there's, you know, finger sticks
are pretty barbaric. Not nearly enough information to really manage the disease well. So we just were
very focused on making an accurate and reliable CGM. And over time, as we recognize the technology
got easier to use, more people are using it, the benefit that can be driven through the whole
spectrum of diabetes as well as pre-diabetes, which are starting to call early stage diabetes now.
And also longevity and health and wellness, there's so much impact that this technology can have.
And I think a big part of that has been making it more reliable, making it easier to use. You know,
all the tools and technology around the user experience is a big part of what makes the technology
so impactful. Yeah, so can we just expand on that a little bit? So on my flight down here to
New Orleans, the person I sat next to, he works for another company and we started talking about
CGM and he basically was like kind of doubting. He was like, why would a person without diabetes
ever wear a continuous glucose monitor? And so I said, well, actually, we are having a
take home trial. And if you would like to, you could put on a stello, which is our product for
people who either have diabetes, not on insulin or who don't have diabetes. And I was, you know,
it's about like looking at your habits, seeing how your glucose responds to food, exercise,
activity, even sleep. So all of these things. So what would you say to some of our clinicians out
there who might think the same thing, right? They might think that a CGM is only four people who
have diabetes. I think it's a question that's been asked many times. A couple of things I think
about is 40% of the US adult population has prediabetes. So I think anyone can benefit from
learning more about how their activities, how their their diet choices impact their glucose.
And I have not met a single person who has worn a CGM and not learned something. I mean,
myself, I don't have diabetes. I wear CGM all the time. And, you know, a lot of it, we're testing
new technology, we're testing new ideas, but you learn a ton. And, you know, the, the goal is to
ensure that, you know, you're not having these large glucose excursions that those of, you know,
don't have diabetes. It still can impact you over time. And so minimizing the glucose excursions.
And for me, it's just a lot not changing what I eat, changing the order of how I eat it. If I eat a
lot of carbohydrates in an empty stomach, I'm going to get a big glucose spike. And if I eat it with
some protein, I don't. And so I've changed breakfast habits. I've changed when I get home from work.
You know, I don't immediately have a beer. I like eat something first. So I think it's everyone
learns something. And we see all kinds of patterns of use. Some people really like to use the CGM
all the time, both as a learning tool, but also a little bit of accountability. And so they,
you know, I think we all I certainly eat differently when I'm wearing a CGM just because
continually reminds me. So I think that's a good thing. And we also have folks that use it
sporadically, occasionally, you know, learn, reinforce those learning. So it's a really powerful
tool. And I think over time, we're going to learn as we see more and more use. We're going to learn
how it's applied. Right. And we're going to see so much from learning, you know, as a HCP out there,
we don't really even know, like, what happens if the glucose is elevated for an hour? What if it's
20 minutes? Like, we're going to just learn so much from this data. Yeah. So can you talk about any
teller listeners, any of the new features that Dexcom has or what we've been working on? We've got
lots. Okay. On the software side, we're doing a lot around therapy optimization for insulin
users. So we have, when you think about our product portfolio, it serves a very large diverse
group of patients. So you've got type one of people type one, you get people type two that
intensively aren't intensive insulin. So taking multiple shots a day, we've got, you know,
basal insulin users. And then we have a broad spectrum of type two patients who are using all kinds
of different medications to lower their glucose. And one of the things we're working on is bringing
new technology for both the physician and the patient to optimize it. So smart basal is one of
those technologies that's in a pilot launch right now. We've got in quite a few clinics across
the US seeing great results. I just saw a patient that within 17 days got to their optimal dose.
Glucose control is so much better when you've got the right dose of basal insulin for that long
acting insulin. So you can see it with the CGM and the patient can see it and everybody feels good.
And I think it's, it's a powerful tool. Right. Because how it looks now in practice for an
HCP to tie trade insulin, they have, they're still looking at finger sticks, right? They're calling
every three days. It could take, I don't know, several months to get to an optimal range. So we're
really trying to help both the patient and the clinician there. Yeah, it's, I mean, it's doing
basal insulin titration without a tool like this is really hard because they start at a dose that
they want, you know, they won't want to give them too much. So they started at usually a pretty
small dose and then, you know, kind of see how that goes and then change the dose. But there's this
interaction then.
has to happen either in the clinic or on the phone.
And it's just this system is designed to automatically
do it in the background based on the CGM data.
And so it really gets the patient.
Because if you're taking a shot at insulin once a day,
and you're not seeing a lot of results
because it's too small of a dose, you're not
going to-- who knows, maybe you should stop taking.
Because you're like, this isn't helping me.
So this new system gets people to that dose quickly,
and they can see the impact in their glucose
and soak in the physician.
And so I think it's going to be a great tool.
We also have a smart bolus coming, which
is a tool around those who are doing fast acting insulin.
You can, basically, it's designed
to help you determine how much insulin to take.
And then, you know, if there's a correction,
bolus needed, it does that too.
And it's all built into the CGM software,
so there's nothing else you have to do.
And so that's one of the things we're doing on the clinician
side is we're implementing clarity into the EHR.
So many of our clinicians are using EHRs
in all the other parts of their practice.
And then to look at the data, they
have to go to clarity, which we all love clarity.
And a lot of clinics have used it daily.
But for many, it's a burden to kind of bounce in between the two
systems.
And so the idea is, let's put all that functionality
right into the EHR.
So we have hundreds of hospitals and clinical sites
onboarding right now with our current integration.
And we're going to continue to evolve that EHR integration
so that we have full clarity functionality built in.
Yeah.
I know so many clinicians out there are waiting for that,
I mean, for sure.
Because already, you have to do so many different things.
Even in terms of app, I've done all this happen.
So that's going to save so much time.
OK, Jake, now we didn't talk about this.
But can you tell our listeners anything about nutrients?
Yeah, yeah. We're really excited about nutrient sense
as a company that we've struck a deal to purchase.
And it is that they've been a partner of DEX
comes for a while.
And what they've been doing is developing
this really cool system that is powered by highly experienced,
certified nutritionists.
And what they do is they work with the patient on a CGM
guided nutrition plan.
And depending on what the patient's trying to achieve,
whether it's weight loss or better metabolic health,
it's all guided by CGM.
And they've been doing this for a while.
And so they've been using our CGMs
and they've built this whole system of software
in a number of nutritionists that basically
are able to build this really engaging experience
when the patient first starts using the CGM.
And what we found is that level of engagement
and really understanding, connecting the dots with the data
and the nutrition is a really powerful tool
to drive the engagement user to use the CGM
and to get the benefits from it.
And so we see some pretty high engagement scores
for people who use this system.
So our goal is to integrate it across all of our products,
to give everyone the option to do
to have that tailored, personalized nutrition plan.
- This is like so near and dear to my heart
because I'm a dietician and this would do in practice.
And so I've been at DEXCOM now eight years,
so almost a decade.
And so yeah, I mean, I've been doing this my whole career.
I'm so happy that it's all coming together.
So excited.
So can we also tell some of our HCPs out there maybe about,
you know, so G7, 15-day is recent on the market.
And I just want to talk maybe about some of the changes
with G7, 15-day and maybe some of the accuracy changes
and what clinicians can expect there
if they aren't already using it.
- Yeah, the 15-day G7 is our latest version of our product.
We just started launching it across all of the channels
in the United States in January.
So it's been out for about, we're coming in six months.
We're seeing really high satisfaction from patients
and clinicians who are using this product.
It basically not only extends the sensor
where to 15 and a half days.
So it's the 15 days plus the 12 hour grace period,
which is designed to make it convenient to change your sensor.
And then it also has improvements
to the algorithm inside the product,
which is what basically calculates glucose reading
from the sensor signals.
And what we've done over many years
is, every time we launch a product,
we learn a lot after it's been out in the market for a while.
We learn, you know, subtle things we can do
to further improve it.
And so we've done that with each of our generations,
we always come out, after about a year or two,
we come out with a new version of the algorithm
in the product.
And so we did that with 15 days.
So it's not only longer lasting, it's more accurate.
And it also part of the algorithm
improvement is around the way the data is presented
to the user.
And so when you look at the glucose graph,
there's a lot smoother.
And what that was was learnings from G7.
And basically, the signal can,
when you're looking at it on G7 10 day,
sometimes it's a little jittery.
And it actually is responding very rapidly to glucose.
But the way that we interpret that now in the 15 days,
that kind of smooths it out a little more.
Patients really like it.
It's really interesting, it's subtle change like that.
It's noticeable.
And we're hearing a lot of feedback about it.
And so patients are noticing that improved accuracy.
So we're very excited about this.
It also, one thing I add is we do have a new patch
that's coming out across the whole product line.
It's starting on 15 day.
We're going to move it onto 10 day as well.
It is a patch that lasts longer.
So even for those users on 10 day,
they'll benefit from it as well.
Because it is 10% more survival of the sensor
with this adhesive.
And it does not-- we'd basically study this
and people with known sensitivities to adhesives
to make sure that it is stickier.
So is it going to cause any more irritation?
And so we stayed up very closely.
And we didn't see any increase in irritation.
So we're really excited to roll that out across the whole
product portfolio.
OK, so is that out now?
Is that on G7 15 day?
It's on products not on all the product
because it's kind of finding its way through the channels.
But yeah, there are users out there.
For the last about six weeks, six weeks ago,
as we saw the first product in market,
patients using it.
And it's just going to continue to flow from there.
So Jake, now that I have you on,
I really think it's important if you
can tell some of our clinicians out there.
Because I know this.
And I know this is near and dear to my heart.
So I would like you to tell them in your view,
you've been at Dexcom for a long time.
You said 22 years and now you're the CEO.
Do you really feel in your heart that we are always taking
the patient and the clinician into consideration
when we are designing a product or thinking about?
Because I know sometimes we get calls
and I don't know, they get mad at us.
And I just want to make sure that everybody knows
that I feel like we really are trying so hard
and we keep the patient in mind.
Do you feel like that?
I do, I think our intent is always
to do the right thing for the patient
and the customer and the customer includes physicians,
the prescribing physicians, treating physicians.
Actually, it includes our partners and the channels
that help distribute the product and the payers
who are paying for this product around the world.
We keep all of their interests in mind.
And so I am very confident that around our culture,
the intent is do the right thing, always empowering patients.
We have to continue to evolve ourselves
to make sure that the patients and physicians
are also feeling that.
So I think that is a really important part
of our evolution going forward.
It's also one of the reasons why we set up
the customer advisory council.
So we set that up earlier this year.
It was a very diverse group of people
who either use our products, wear their products
or a family member uses it.
And it was really the goal was to get unfiltered feedback
about what we could do to improve the user experience
around our products.
We have the most accurate, longest lasting product today,
but there's still times where we can improve.
And so that was, you know, we like hearing how good we are,
but we also need to hear how we can improve.
And so that whole council was designed around that.
We just released a report that's on our website
that basically captures the feedback from that council
and what we're doing in response to it.
And so there's a lot of exciting detail in there
around some of the new product features,
service changes, all the things that we're doing.
To continue to ensure that we have
the absolute best glucose sensing experience for users
as well as the setting the bar for customer experience.
We want everyone to have an amazing experience
when these are the next product.
- And then how is that getting reported out?
Do we have a channel to get that out
or is that only for internal use
or how would that get disseminated down
to the clinician and/or the patient?
- Yeah, that's a great question.
It's available on our website for anybody to download.
There's a PDF there.
We also have hard copies that we've been handing out
as our sales team is providing that
to clinicians on the field.
We're getting really good.
I mean, it's only we just published it this week.
And we're already hearing good feedback from the field,
from clinicians who've read it and said,
"Wow, this is great stuff."
So I encourage anyone to take a look at it.
- Yeah, Jake, I just want to say,
I mean, I just think that's so important, right?
I mean, sometimes we have to get feedback.
We learn, we change, and we iterate,
and that's an important part of the process.
And that's what we do at Dexcom,
and we take it to heart for sure.
- So Jake, now that we're here at ADA,
what else can we share with our listeners today?
What new research or anything?
Is anything new come out that we want to tell them about?
- Well, yeah, it's pretty exciting.
Yesterday we wrote out some results
from a randomized control trial that we just ran.
and it was the first time we've released these results.
Dextreum is pint.
all kinds of innovative technology and features that drive use of the CGM and but we also are driving outcomes, clinical outcomes, and we have a history of generating the evidence that is used for access for patients that drives access for patients around the world to this technology.
We started with an intensive insulin study back in 2016. It was called Diamond Study. We ran that. That was really the cornerstone for access for type 2 and some type 1 intensive insulin users.
Then we ran the mobile study and we reported that out in 2021. That was a basil insulin users and showed the significant benefit CGM has in that patient population.
Yesterday, the connect study was read out. That was a large randomized control trial showing the benefits of CGM and people who typed you diabetes that don't use insulin to lower their glucose but they take a combination of all of the other glucose lowering medications.
We had a really good cohort of patients that whether that I met Foreman or a GLP1, SGLT2, and even a portion of the study about 8% weren't using any glucose lowering medication and what we showed was a really powerful result in those that were using CGM to manage your diabetes.
There's a control arm that just was using finger sticks. I think the average was they took three finger sticks a week compared that to CGM data real time.
In the benefit, the Dexcom CGM drove in that patient population was significant. Some of the most significant improvements in glycemic control we measured it using A1C.
The population as a whole, we saw almost a 1% A1C drop which is very significant clinically for those users.
Some of the most impressive results were those using GLP1s alone with some of the highest improvement was in that group as well as those who were using just met Foreman.
I think it shows the spectrum of CGM and what it can do no matter what glucose lowering medication is being used.
Over time, what we're also going to see is the intensification of medication once patients start learning about the other components around lifestyle and what actual food is doing to their glucose control.
You get that education there and then you can start dialing in, like I talked about at the beginning, the therapy optimization and getting the medication doses and the type getting that right, really, really powerful combination.
Yeah, and I think, you know, it's even important. I mean, when a patient takes the GLP1 or a person living with diabetes takes the GLP1, they probably should see what their glucose is doing, right?
I mean, is it going too low or what's happening there? So, and I think that that's important, whereas maybe some physicians would think that if they're, oh, if they're on a GLP1, they don't need to be on a CGM, but the reality is it helps.
It helps a lot and the results are pretty clear. We've shown from clinical trials before we've shown this, but in this trial, it's a very powerful randomized control on trials.
So it is those results in GLP1 users were pretty phenomenal and it's really driven by the fact that the two, although they're both used in diabetes, they do work on very different things, right?
The GLP1 is all about the amount of food consumed and the body's processing of that food. CGM is all about what food, what type of food, what order, like just better understanding the education.
So you've got those two things working together is a really powerful combination to drive outcomes in these patients living with diabetes.
And I just don't have outcomes, but I also think it helps to, for the person wearing a product or taking a GP1, I think it helps to increase like engagement and they can be more engaged in their treatment, their choices.
And I, you know, I've talked to a lot of people wearing it and I think that they're happy with it.
They are, I mean, you with the CGM, it's the only tool that can show you in real time how that medication is working.
And, you know, I think with GLP1's people are excited when they see what their glucose control does. And if they, you know, they skip their dose, they're going to see also what it looks like.
And I think that is, it's a tool that helps just optimize things. And the patient reported outcomes from the connect study were also read out yesterday portion of them.
And, you know, diabetes distress was much lower.
But there has been this question, clinicians have asked, like, are people with type 2 diabetes that aren't taking insulin, are they going to use this product all the time?
In the next day, we saw 97% utilization of the CGM. And that was really significant because the patients really liked using the product.
They really thought they were getting benefit. And so they wanted to continue using it after the study.
We are doing an extension of the study where the groups are wearing CGM. And we'll report those out later next year.
Jake, before we wrap up today, is there anything else that you want to tell our clinicians that are listening in out there, you know, either about something that's coming, something that you didn't get to talk to them about today.
Anything about CGM in general, technology before we wrap up.
Well, I think we now have a body of evidence that shows CGM is incredibly impactful in all people's diabetes, the whole spectrum.
And so we're working very hard to get more insurance coverage for CGM. Right now, half of the people that have commercial insurance for our covered for CGM, if they have diabetes.
So that's new. One of the things that's important, I think, is the coverage landscape for CGM continues to evolve very rapidly.
So the important thing is to stay up on that. Our teams are out there trying to help make sure everyone is aware of just how much benefit can be had by this product and who can have access to it.
And the goal right now is anyone diabetes should have access to CGM. We're going to continue to drive that around the world for all users because of the benefit this technology has.
And what about people though who don't have diabetes? Do we want to mention that?
When you think about health and longevity, I think as we continue to study that, we're going to see that glucose is a very important vital sign that needs to be monitored and people need to have education about it.
Jake, thank you so much for being here today. This is like an amazing episode. Thank you for spending time with us.
And we'll get some feedback. And if we need to have you back on, will you come on? I would. I'd love to. Yeah, thank you, sure.
Thank you.
Thanks for tuning in to another episode of the glucose tech podcast. For more learning resources, head to glucosetech.com and we'll see you next time.
Podcast Summary
Key Points:
DEXCOM’s CGM technology has evolved significantly over the past two decades, becoming more accurate, user-friendly, and integrated with smartphones and EHRs.
New tools like Smart Basal and Smart Bolus are enabling clinicians to optimize insulin therapy, with patients achieving optimal doses in as little as 17 days.
The 15-day G7 sensor offers longer wear time, improved algorithm accuracy, smoother glucose trend visualization, and a 10% increase in sensor adhesion durability.
DEXCOM has partnered with Nutrient Sense to offer CGM-guided, personalized nutrition plans, enhancing patient engagement and metabolic health.
Clinical trials, including the CONNECT study, show that CGM significantly improves glycemic control (up to 1% A1C reduction) and reduces diabetes distress across all diabetes types, including non-insulin users.
CGM benefits extend beyond diabetes, with growing evidence that glucose monitoring supports metabolic health and wellness in prediabetes and healthy individuals.
DEXCOM has established a Customer Advisory Council to gather real-world feedback, leading to iterative product improvements and better user experiences.
DEXCOM is actively working to expand insurance coverage and ensure equitable access to CGM for all patients with diabetes, with a long-term vision of universal access.
Summary:
DEXCOM’s continuous glucose monitoring (CGM) technology has advanced dramatically over the past two decades, evolving from a physician-only tool to a user-friendly, clinically impactful solution for patients with diabetes and even those without. In recent developments, DEXCOM launched the 15-day G7 sensor, offering longer wear time, improved algorithm accuracy, and smoother glucose trend visualization, with a new adhesive patch increasing sensor durability without causing irritation. The company is introducing key clinical tools like Smart Basal and Smart Bolus to help clinicians optimize insulin therapy, with real-world results showing patients reach optimal doses in as little as 17 days.
A major highlight is the CONNECT study, a large randomized trial showing that CGM improves glycemic control—reducing A1C by nearly 1%—and lowers diabetes distress across all types of diabetes, including non-insulin users. DEXCOM’s partnership with Nutrient Sense enables personalized, CGM-driven nutrition plans, boosting patient engagement. The company emphasizes that glucose monitoring is not just for diabetes but also vital for metabolic health and longevity.
To ensure continuous improvement, DEXCOM runs a Customer Advisory Council that provides unfiltered user feedback. Additionally, the company is actively advocating for broader insurance coverage, aiming to make CGM accessible to all patients with diabetes. These innovations reflect a strategic commitment to empowering both patients and clinicians with actionable, real-time glucose insights that drive better health outcomes.
FAQs
Smart Basal is a pilot tool that helps clinicians titrate basal insulin doses more efficiently using CGM data. Patients can reach their optimal insulin dose in as little as 17 days, with visible improvements in glucose control and overall health.
The G7 15-day sensor extends wear time to 15.5 days with a 12-hour grace period and includes algorithm improvements for smoother, more accurate glucose readings. It also offers better data presentation and improved long-term sensor adhesion.
Yes, non-diabetic individuals can benefit by learning how diet, activity, and sleep affect their glucose levels. Many users report changes in habits, such as meal timing or food ordering, which lead to better metabolic health.
Nutrient Sense is a nutrition planning service powered by certified nutritionists that uses CGM data to create personalized, CGM-guided nutrition plans. It’s being integrated across all Dexcom products to enhance user engagement and outcomes.
Dexcom is integrating Clarity software directly into EHR systems so clinicians can access patient glucose data seamlessly, reducing time spent switching between platforms and improving clinical decision-making.
The CONNECT study showed that people with type 2 diabetes not on insulin who used CGM had a significant 1% drop in A1C and reduced diabetes distress. These results demonstrate strong benefits across all glucose-lowering medication types.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.